553 related articles for article (PubMed ID: 30093503)
1. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Drilon A; Ou SI; Cho BC; Kim DW; Lee J; Lin JJ; Zhu VW; Ahn MJ; Camidge DR; Nguyen J; Zhai D; Deng W; Huang Z; Rogers E; Liu J; Whitten J; Lim JK; Stopatschinskaja S; Hyman DM; Doebele RC; Cui JJ; Shaw AT
Cancer Discov; 2018 Oct; 8(10):1227-1236. PubMed ID: 30093503
[TBL] [Abstract][Full Text] [Related]
2. Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.
Yun MR; Kim DH; Kim SY; Joo HS; Lee YW; Choi HM; Park CW; Heo SG; Kang HN; Lee SS; Schoenfeld AJ; Drilon A; Kang SG; Shim HS; Hong MH; Cui JJ; Kim HR; Cho BC
Clin Cancer Res; 2020 Jul; 26(13):3287-3295. PubMed ID: 32269053
[TBL] [Abstract][Full Text] [Related]
3. Bioanalytical assay for the new-generation ROS1/TRK/ALK inhibitor repotrectinib in mouse plasma and tissue homogenate using liquid chromatography-tandem mass spectrometry.
Li W; Perpinioti N; Schinkel AH; Beijnen JH; Sparidans RW
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 May; 1144():122098. PubMed ID: 32278292
[TBL] [Abstract][Full Text] [Related]
4. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Drilon A; Siena S; Ou SI; Patel M; Ahn MJ; Lee J; Bauer TM; Farago AF; Wheler JJ; Liu SV; Doebele R; Giannetta L; Cerea G; Marrapese G; Schirru M; Amatu A; Bencardino K; Palmeri L; Sartore-Bianchi A; Vanzulli A; Cresta S; Damian S; Duca M; Ardini E; Li G; Christiansen J; Kowalski K; Johnson AD; Patel R; Luo D; Chow-Maneval E; Hornby Z; Multani PS; Shaw AT; De Braud FG
Cancer Discov; 2017 Apr; 7(4):400-409. PubMed ID: 28183697
[TBL] [Abstract][Full Text] [Related]
5. Repotrectinib: First Approval.
Dhillon S
Drugs; 2024 Feb; 84(2):239-246. PubMed ID: 38279972
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central β-Sheet 6 [Cβ6] Mutation [L2086F]).
Ou SI; Hagopian GG; Zhang SS; Nagasaka M
J Thorac Oncol; 2024 May; 19(5):706-718. PubMed ID: 38070596
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
Lee J; Sun JM; Lee SH; Ahn JS; Park K; Choi Y; Ahn MJ
Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630
[TBL] [Abstract][Full Text] [Related]
8. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
9. Repotrectinib in
Drilon A; Camidge DR; Lin JJ; Kim SW; Solomon BJ; Dziadziuszko R; Besse B; Goto K; de Langen AJ; Wolf J; Lee KH; Popat S; Springfeld C; Nagasaka M; Felip E; Yang N; Velcheti V; Lu S; Kao S; Dooms C; Krebs MG; Yao W; Beg MS; Hu X; Moro-Sibilot D; Cheema P; Stopatschinskaja S; Mehta M; Trone D; Graber A; Sims G; Yuan Y; Cho BC;
N Engl J Med; 2024 Jan; 390(2):118-131. PubMed ID: 38197815
[TBL] [Abstract][Full Text] [Related]
10. Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations.
Murray BW; Rogers E; Zhai D; Deng W; Chen X; Sprengeler PA; Zhang X; Graber A; Reich SH; Stopatschinskaja S; Solomon B; Besse B; Drilon A
Mol Cancer Ther; 2021 Dec; 20(12):2446-2456. PubMed ID: 34625502
[No Abstract] [Full Text] [Related]
11. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Zou HY; Li Q; Engstrom LD; West M; Appleman V; Wong KA; McTigue M; Deng YL; Liu W; Brooun A; Timofeevski S; McDonnell SR; Jiang P; Falk MD; Lappin PB; Affolter T; Nichols T; Hu W; Lam J; Johnson TW; Smeal T; Charest A; Fantin VR
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3493-8. PubMed ID: 25733882
[TBL] [Abstract][Full Text] [Related]
12. Targeting TRK: A fast-tracked application of precision oncology and future directions.
Kojadinovic A; Laderian B; Mundi PS
Crit Rev Oncol Hematol; 2021 Sep; 165():103451. PubMed ID: 34389458
[TBL] [Abstract][Full Text] [Related]
13. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
14. Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors.
Keddy C; Shinde P; Jones K; Kaech S; Somwar R; Shinde U; Davare MA
Mol Cancer Ther; 2022 Feb; 21(2):336-346. PubMed ID: 34907086
[TBL] [Abstract][Full Text] [Related]
15. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Katayama R; Gong B; Togashi N; Miyamoto M; Kiga M; Iwasaki S; Kamai Y; Tominaga Y; Takeda Y; Kagoshima Y; Shimizu Y; Seto Y; Oh-Hara T; Koike S; Nakao N; Hanzawa H; Watanabe K; Yoda S; Yanagitani N; Hata AN; Shaw AT; Nishio M; Fujita N; Isoyama T
Nat Commun; 2019 Aug; 10(1):3604. PubMed ID: 31399568
[TBL] [Abstract][Full Text] [Related]
16. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
Drilon A; Nagasubramanian R; Blake JF; Ku N; Tuch BB; Ebata K; Smith S; Lauriault V; Kolakowski GR; Brandhuber BJ; Larsen PD; Bouhana KS; Winski SL; Hamor R; Wu WI; Parker A; Morales TH; Sullivan FX; DeWolf WE; Wollenberg LA; Gordon PR; Douglas-Lindsay DN; Scaltriti M; Benayed R; Raj S; Hanusch B; Schram AM; Jonsson P; Berger MF; Hechtman JF; Taylor BS; Andrews S; Rothenberg SM; Hyman DM
Cancer Discov; 2017 Sep; 7(9):963-972. PubMed ID: 28578312
[TBL] [Abstract][Full Text] [Related]
17. TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers.
Thawani R; Repetto M; Keddy C; Nicholson K; Jones K; Nusser K; Beach CZ; Harada G; Drilon A; Davare MA
bioRxiv; 2024 Jan; ():. PubMed ID: 38293020
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Menichincheri M; Ardini E; Magnaghi P; Avanzi N; Banfi P; Bossi R; Buffa L; Canevari G; Ceriani L; Colombo M; Corti L; Donati D; Fasolini M; Felder E; Fiorelli C; Fiorentini F; Galvani A; Isacchi A; Borgia AL; Marchionni C; Nesi M; Orrenius C; Panzeri A; Pesenti E; Rusconi L; Saccardo MB; Vanotti E; Perrone E; Orsini P
J Med Chem; 2016 Apr; 59(7):3392-408. PubMed ID: 27003761
[TBL] [Abstract][Full Text] [Related]
19. NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.
Drilon A; Horan JC; Tangpeerachaikul A; Besse B; Ou SI; Gadgeel SM; Camidge DR; van der Wekken AJ; Nguyen-Phuong L; Acker A; Keddy C; Nicholson KS; Yoda S; Mente S; Sun Y; Soglia JR; Kohl NE; Porter JR; Shair MD; Zhu V; Davare MA; Hata AN; Pelish HE; Lin JJ
Cancer Discov; 2023 Mar; 13(3):598-615. PubMed ID: 36511802
[TBL] [Abstract][Full Text] [Related]
20. First macrocyclic 3
Basit S; Ashraf Z; Lee K; Latif M
Eur J Med Chem; 2017 Jul; 134():348-356. PubMed ID: 28431340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
